MATRIX-RARE gets access to two new drugs from Servier

MATRIX-RARE is a clinical study for patients with rare and treatment‑resistant cancers, offering personalized treatment based on the tumour’s molecular characteristics. Since its launch in 2025, the study has gradually been expanded with additional treatment options.

The study is now further strengthened through a collaboration with the pharmaceutical company Servier, which will provide the targeted therapies Voranigo and Tibsovo. These drugs target mutations in the IDH1 and IDH2-genes and may be relevant for selected patient groups in the study.

The expansion means that more patients can be offered treatment within MATRIX-RARE, while also providing an important opportunity to develop new knowledge about how targeted therapy can benefit patients with rare cancer types.

We are very pleased about this, and we hope it can help more patients with rare cancers, says study lead Åslaug Helland.